Peptic ulcer bacterium alters the body's defence system

NewsGuard 100/100 Score

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden. The discovery may lead to new treatments against the common peptic ulcer bacterium.

About half of the world's population carries Helicobacter pylori, mainly in the stomach. Most infected individuals never experience any symptoms, but around 10% get peptic ulcers and around 1% develop stomach cancer. 'Carriers were often infected as children and if not treated with antibiotics, the bacterium remains in the body for life. The immune system alone is unable to eliminate the bacterium, and now we understand better why', says biologist Bert Kindlund, the author of the thesis.

The study shows that a type of cells in the immune system called regulatory T cells down-regulate the body's defence against Helicobacter pylori and thereby enable the bacterium to develop a chronic infection. 'If we could control the regulatory T cells, we could strengthen the immune system and help the body eliminate the bacterium. This could be a new treatment strategy against Helicobacter pylori', Kindlund continues.

In addition, the bacterium makes the immune system increase the number of regulatory T cells in the lining of the stomach. This also occurs with stomach cancer. 'An important question is where the increased number of regulatory T cells in the stomach lining come from. Knowing the answer to this question could help us develop a treatment for stomach cancer. What we have found so far is that the regulatory T cells are actively recruited from the bloodstream into the tumour, and once there they start multiplying faster', says Kindlund.

Full bibliographic information: The thesis is based on the following papers:
I. Bert Kindlund, Åsa Sjöling, Malin Hansson, Anders Edebo, Lars-Erik Hansson, Henrik Sjövall, Ann-Mari Svennerholm and B. Samuel Lundin
FOXP3-expressing CD4+ T-cell numbers increase in areas of duodenal gastric metaplasia and are associated to CD4+ T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter 2009 June; 14 (3): 192-201
II. Karin Enarsson, Anna Lundgren, Bert Kindlund, Mikael Hermansson, Giovanna Roncador, Alison H Banham, B. Samuel Lundin and Marianne Quiding-Järbrink
Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 2006 Dec; 121 (3): 358-68
III. B. Samuel Lundin, Karin Enarsson, Bert Kindlund, Anna Lundgren, Erik Johnsson, Marianne Quiding-Järbrink and Ann-Mari Svennerholm
The local and systemic T-cell response to Helicobacter pylori in gastric cancer patients is characterised by production of interleukin-10. Clin Immunol 2007 Nov; 125 (2) 205-13

Comments

  1. Christine Christine United States says:

    My friend is 21 years old and he just found out that he has cancer around an ulcer and his doctor told him that the cancer will never go away, the only thing is to keep doing Chemo Therapy. I dont understand the whole concept, only is there a chance he will survive and get rid of this?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions